Review ArticleReviews and Contemporary Updates

Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia

Cameron Grigg, Daniel Anderson and James Earnshaw
Ochsner Journal June 2017, 17 (2) 157-161;

REFERENCES

  1. ↵
    1. Rendu M
    Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux. Bull Mem Soc Med Hop Paris. 1896; 13: 731- 733.
    OpenUrl
    1. Harper PS
    1. Osler W
    On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. : Harper PS, Landmarks in Medical Genetics: Classic Papers with Commentaries. New York, NY: Oxford University Press; 2004: 17.
  3. ↵
    1. Weber FP
    Multiple hereditary developmental angiomata with recurring epistaxis. Proc R Soc Med. 1908; 1(Clin Sect):65-66.
  4. ↵
    1. Kjeldsen AD,
    2. Vase P,
    3. Green A
    Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999 1; 245 1: 31- 39. pmid:10095814
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Bideau A,
    2. Plauchu H,
    3. Brunet G,
    4. Robert J
    Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. Popul. 1989 9; 44 1: 3- 22. pmid:12157905
    OpenUrlPubMed
  6. ↵
    1. McAllister KA,
    2. Grogg KM,
    3. Johnson DW,
    4. et al.
    Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994 12; 8 4: 345- 351. pmid:7894484
    OpenUrlCrossRefPubMedWeb of Science
    1. Johnson DW,
    2. Berg JN,
    3. Baldwin MA,
    4. et al.
    Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996 6; 13 2: 189- 195. pmid:8640225
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Gallione CJ,
    2. Repetto GM,
    3. Legius E,
    4. et al.
    A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004 3 13; 363 9412: 852- 859. pmid:15031030
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Dupuis-Girod S,
    2. Bailly S,
    3. Plauchu H
    Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost. 2010 7; 8 7: 1447- 1456. doi: 10.1111/j.1538-7836.2010.03860.x. pmid:20345718
    OpenUrlCrossRefPubMed
  10. ↵
    1. McDonald J,
    2. Bayrak-Toydemir P,
    3. Pyeritz RE
    Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011 7; 13 7: 607- 616. doi: 10.1097/GIM.0b013e3182136d32. pmid:21546842
    OpenUrlCrossRefPubMed
  11. ↵
    1. Sadick H,
    2. Naim R,
    3. Gössler U,
    4. Hörmann K,
    5. Riedel F
    Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med. 2005 1; 15 1: 15- 19. pmid:15583822
    OpenUrlPubMedWeb of Science
  12. ↵
    1. Shao ES,
    2. Lin L,
    3. Yao Y,
    4. Boström KI
    Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009 9 3; 114 10: 2197- 2206. doi: 10.1182/blood-2009-01-199166. pmid:19506300
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. AAssar OS,
    2. Friedman CM,
    3. White RI Jr.
    The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991 9; 101 9: 977- 980. pmid:1886446
    OpenUrlPubMedWeb of Science
  14. ↵
    1. Ference BA,
    2. Shannon TM,
    3. White RI Jr.,
    4. Zawin M,
    5. Burdge CM
    Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest. 1994 11; 106 5: 1387- 1390. pmid:7956388
    OpenUrlCrossRefPubMedWeb of Science
    1. Jessurun GA,
    2. Kamphuis DJ,
    3. van der Zande FH,
    4. Nossent JC
    Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg. 1993 9; 95 3: 193- 198. pmid:8242961
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Smith CR Jr.,
    2. Bartholomew LG,
    3. Cain JC
    Hereditary hemorrhagic telangiectasia and gastrointestinal hemorrhage. Gastroenterology. 1963 1; 44: 1- 6. pmid:13989363
    OpenUrlPubMed
  17. ↵
    1. Shovlin CL,
    2. Guttmacher AE,
    3. Buscarini E,
    4. et al.
    Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000 3 6; 91 1: 66- 67. pmid:10751092
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Faughnan ME,
    2. Palda VA,
    3. Garcia-Tsao G,
    4. et al.
    HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011 2; 48 2: 73- 87. doi: 10.1136/jmg.2009.069013. pmid:19553198
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Strach K,
    2. Schröck A,
    3. Wilhelm K,
    4. et al.
    Endovascular treatment of epistaxis: indications, management, and outcome. Cardiovasc Intervent Radiol. 2011 12; 34 6: 1190- 1198. doi: 10.1007/s00270-011-0155-5. pmid:21472510
    OpenUrlCrossRefPubMed
  20. ↵
    1. Pope LE,
    2. Hobbs CG
    Epistaxis: an update on current management. Postgrad Med J. 2005 5; 81 955: 309- 314. pmid:15879044
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Karnezis TT,
    2. Davidson TM
    Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012 3; 122 3: 495- 497. doi: 10.1002/lary.22501. pmid:22147664
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Yaniv E,
    2. Preis M,
    3. Hadar T,
    4. Shvero J,
    5. Haddad M
    Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. 2009 2; 119 2: 284- 288. doi: 10.1002/lary.20065. pmid:19160429
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Yaniv E,
    2. Preis M,
    3. Shevro J,
    4. Nageris B,
    5. Hadar T
    Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology. 2011 6; 49 2: 214- 216. doi: 10.4193/Rhino09.201. pmid:21743879
    OpenUrlCrossRefPubMed
  24. ↵
    1. Geisthoff UW,
    2. Seyfert UT,
    3. Kübler M,
    4. Bieg B,
    5. Plinkert PK,
    6. König J
    Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014 9; 134 3: 565- 571. doi: 10.1016/j.thromres.2014.06.012. pmid:25005464
    OpenUrlCrossRefPubMed
  25. ↵
    1. Hoag JB,
    2. Terry P,
    3. Mitchell S,
    4. Reh D,
    5. Merlo CA
    An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010 4; 120 4: 838- 843. doi: 10.1002/lary.20818. pmid:20087969
    OpenUrlCrossRefPubMed
  26. ↵
    1. Luk L,
    2. Mace JC,
    3. Bhandarkar ND,
    4. Sautter NB
    Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Int Forum Allergy Rhinol. 2014 8; 4 8: 640- 645. doi: 10.1002/alr.21328. pmid:24719397
    OpenUrlCrossRefPubMed
  27. ↵
    1. Boyer H,
    2. Fernandes P,
    3. Le C,
    4. Yueh B
    Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2015 5; 5 5: 435- 440. doi: 10.1002/alr.21484. pmid:25643928
    OpenUrlCrossRefPubMed
  28. ↵
    1. Boyer H,
    2. Fernandes P,
    3. Duran O,
    4. Hunter D,
    5. Goding G
    Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study. Int Forum Allergy Rhinol. 2011 Jul-Aug; 1 4: 319- 323. pmid:22287439
    OpenUrlCrossRefPubMed
  29. ↵
    1. Harvey RJ,
    2. Kanagalingam J,
    3. Lund VJ
    The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol. 2008 Mar-Apr; 22 2: 182- 187. doi: 10.2500/ajr.2008.22.3145. pmid:18416977
    OpenUrlCrossRefPubMed
  30. ↵
    1. Pau H,
    2. Carney AS,
    3. Murty GE
    Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol Allied Sci. 2001 4; 26 2: 93- 98. pmid:11309047
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Richer SL,
    2. Geisthoff UW,
    3. Livada N,
    4. et al.
    The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy. 2012 Sep-Oct; 26 5: 401- 404. doi: 10.2500/ajra.2012.26.3809. pmid:23168156
    OpenUrlCrossRefPubMed
  32. ↵
    1. Dupuis-Girod S,
    2. Ginon I,
    3. Saurin JC,
    4. et al.
    Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012 3 7; 307 9: 948- 955. doi: 10.1001/jama.2012.250. pmid:22396517
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Dupuis-Girod S,
    2. Ambrun A,
    3. Decullier E,
    4. et al.
    ELLIPSE Study: a phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs. 2014 May-Jun; 6 3: 794- 799. doi: 10.4161/mabs.28025. pmid:24481211
    OpenUrlCrossRefPubMed
  34. ↵
    1. Chen S 4th.,
    2. Karnezis T,
    3. Davidson TM
    Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011 3; 121 3: 644- 646. doi: 10.1002/lary.21345. pmid:21344447
    OpenUrlCrossRefPubMed
  35. ↵
    1. Dupuis-Girod S,
    2. Ambrun A,
    3. Decullier E,
    4. et al.
    Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA. 2016 9 6; 316 9: 934- 942. doi: 10.1001/jama.2016.11387. pmid:27599328
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords